Core Viewpoint - A new generation of fund managers is emerging in the public fund industry, demonstrating impressive performance by capitalizing on structural opportunities in the new consumption and innovative pharmaceutical sectors [1][2][4]. Group 1: Performance of Young Fund Managers - As of June 20, 2025, five out of the top ten actively managed equity funds have managers with less than three years of experience [2]. - Notable performances include Liang Furui's Changcheng Pharmaceutical Industry Selected Mixed Fund, which achieved a return of 71.21% this year, and was his first fund managed since its establishment in October 2023 [2]. - Another example is the Huazhong Pharmaceutical Biotechnology Stock Fund, managed by Sang Xiangyu, which has also exceeded a 60% return this year [2]. Group 2: Investment Focus and Background - Young fund managers have successfully identified opportunities in the innovative pharmaceutical sector, with many having strong professional backgrounds in relevant fields [4]. - Liang Furui has six years of experience in pharmaceutical research, while Sang Xiangyu has a dual background in bioengineering and economics, and Liu Haihao has been involved in consumer sector research for several years before becoming a fund manager [4]. Group 3: Market Conditions and Fund Establishment - The timing of fund establishment has been favorable, with several top-performing funds launched in late 2023, allowing managers to fully benefit from the rising innovative pharmaceutical market [5]. - The rapid establishment of these funds, often in a small scale, has enabled fund companies to effectively capitalize on market opportunities [5]. Group 4: Balancing Risk and Return - While young fund managers have shown strong performance, there is a need for them to learn how to manage drawdowns effectively, especially in a cyclical market [7]. - Funds with concentrated holdings, such as the Zhonghang Preferred Navigation Mixed Fund, have experienced significant volatility, highlighting the risks associated with aggressive investment strategies [7][8]. - Industry experts emphasize the importance of providing young managers with opportunities while also encouraging a shift towards long-term, value-oriented investment strategies as their fund sizes grow [8].

Core Insights - The average return of actively managed equity funds has significantly improved, reaching 15.1% year-to-date as of August 6, with over 500 funds hitting historical net asset value highs [1][2] - There is a stark performance disparity among funds, with top performers achieving returns close to 130% while laggards have seen declines exceeding 18% [1][3] - The strong performance of leading funds is attributed to successful investments in sectors such as innovative pharmaceuticals, technology, and new consumer trends [2][3] Performance Summary - As of August 6, 127 actively managed equity funds have returns exceeding 50%, with 23 funds surpassing 80%, and 6 funds doubling their net asset value this year [2] - Specific funds like Changcheng Pharmaceutical Industry Select Mixed Fund and Bank of China Hong Kong Stock Connect Pharmaceutical Mixed Fund have returns of 129.97% and 117.54% respectively [2] - Funds focusing on innovative pharmaceuticals have been particularly successful, with several funds achieving returns over 90% in related sectors [2] Fund Management Trends - A significant number of high-performing funds are now implementing purchase limits due to increased investor interest and inflows, with nearly 30 funds announcing restrictions on large subscriptions [4] - Recent fund issuance has also seen a resurgence, with several funds raising over 1 billion yuan, indicating a growing market interest [4] - The trend of increasing fund management activity suggests that equity funds are becoming a key avenue for reallocating household savings [4] Market Outlook - The ongoing supportive policies for the capital market are expected to enhance investor risk appetite, with potential catalysts in technology, high-end manufacturing, and consumer sectors [5] - The release of semi-annual earnings from listed companies is anticipated to improve the effectiveness of investment strategies, particularly in sectors with concentrated catalysts [5]

Group 1 - The average return of actively managed equity funds has reached 13.74% year-to-date as of July 28, with over 90% of more than 4,000 funds achieving positive returns [1] - Nearly 400 funds have returns exceeding 30%, and around 60 funds have returns above 60% [1] - A significant number of funds have doubled their returns this year, with specific funds like Changcheng Medical Industry Select Mixed Fund at 120.89%, Bank of China Hong Kong Stock Connect Medical Mixed Fund at 112.25%, and Yongying Medical Innovation Smart Selection Mixed Fund at 109.01% [1] Group 2 - The market recovery has sparked enthusiasm among fund companies, with 48 equity funds currently in issuance and 39 more set to be issued [1] - Notable fund managers from various firms, including Yongying Fund and Guojin Fund, are launching new funds [1] - Since June 23, high-risk preference funds such as private equity funds and financing funds have played a crucial role in driving market upward momentum [2] - The redemption situation for actively managed equity funds has improved compared to last year, and there is potential for a slight net subscription in the second half of the year [2]

Group 1 - The innovative drug sector has seen significant performance this year, with multiple funds achieving net value doubling, and the top performer nearing a 140% return, leading to a suspension of new subscriptions [1][3] - As of July 28, the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund (QDII), reported a return of 139.12%, attracting substantial inflows [3][4] - Other notable funds include Changcheng Pharmaceutical Industry Selected Mixed Fund with a return of 129.35% and Zhongyin Hong Kong Stock Connect Pharmaceutical Mixed Fund at 119.64% [4] Group 2 - The innovative drug sector remains a focal point for market attention, with strong inflows into various innovative drug-themed ETFs, indicating robust investor interest [7] - On July 30, Huabao Hong Kong Stock Connect Innovative Drug ETF surged nearly 9%, prompting the fund company to issue a risk alert due to high premium rates [7][9] - The trading volume for Huabao Hong Kong Stock Connect Innovative Drug ETF reached 2.502 billion yuan, with a turnover rate of 568.61%, reflecting intense market activity [9] Group 3 - Fund managers highlight the ongoing support from policies, continuous R&D advancements, and accelerated internationalization as key factors for the innovative drug sector's positive outlook [9][10] - Upcoming clinical data and academic conferences, such as the European Society of Cardiology Congress and the European Society for Medical Oncology Congress, are expected to catalyze further developments in the sector [9] - The internationalization of China's innovative drug industry is gaining momentum, with numerous product collaboration agreements with multinational companies, enhancing investor confidence [10]

Group 1 - The performance of actively managed equity funds has significantly improved this year, with over 90% achieving positive returns and a notable emergence of "doubling funds" [1][2] - As of July 28, the average return of actively managed equity funds is 13.74%, with nearly 400 funds exceeding 30% returns and around 60 funds surpassing 60% [1] - Several funds have reported returns exceeding 100%, including the Changcheng Medical Industry Selected Mixed Fund at 120.89% and the Huatai-PB Hang Seng Innovation Drug ETF [1][2] Group 2 - Funds heavily invested in the innovative drug sector have shown strong performance, with the sector continuing to rise as of July 29, indicating potential for more "doubling funds" [2] - Other sectors such as technology and new consumption are also performing well, with funds like the GF Growth Leading Mixed Fund achieving a return of 90.5% [2] - The risk appetite of private equity and financing funds has played a crucial role in driving market uptrends since June 23, contributing to a structural market rally [2] Group 3 - The market recovery has sparked enthusiasm among fund companies, with 48 equity funds currently in issuance and 39 more set to launch soon [3] - Public funds have increased their stock positions significantly, with the average allocation for equity mixed funds rising to approximately 85.99% as of July 25, up by 2.05 percentage points from July 18 [3]

Core Insights - The second quarter saw explosive growth in several fund products, with some "mini funds" experiencing remarkable reversals, notably the Changcheng Medical Industry Selected Mixed Fund, which surged from 0.36 billion to 11.32 billion, a growth of over 30 times [1][2] - Fund managers adopted a more aggressive approach in a volatile market, increasing equity positions and significantly adjusting their heavy holdings, focusing on cutting-edge technology sectors such as artificial intelligence computing, innovative pharmaceuticals, and controllable nuclear fusion [1][3] Fund Performance - The Changcheng Fund's products stood out, with the Changcheng Medical Industry Selected Mixed Fund achieving over 30 times growth, while the Changcheng Prosperity Growth Mixed Fund increased from 0.7 billion to 3.2 billion [2] - The Zhongou Fund also saw significant increases, with the Zhongou Digital Economy Mixed Fund's A-class shares exceeding 220 million subscriptions, and the total fund size growing from less than 800 million to over 9 billion, a more than 10-fold increase [2] - The Zhongou Information Technology Mixed Fund's total subscriptions surpassed 900 million, with a total size exceeding 1 billion, growing over 8 times from the previous quarter [2] Portfolio Adjustments - Fund managers generally opted for aggressive strategies, with the Changcheng Medical Industry Selected Mixed Fund increasing its equity position from 72.48% to 75.89%, focusing on the innovative pharmaceutical sector [3] - The Yongying Fund's products underwent significant portfolio changes, with the Yongying Technology Selected Fund completely renewing its top ten heavy holdings, including companies like Xinyi Technology and Zhongji Xuchuang [3][4] Strategic Focus Areas - Fund managers are strategically focusing on cutting-edge technology sectors, particularly artificial intelligence computing, which is gaining attention due to the increasing demand for model/application and computing power investments [5] - The innovative pharmaceutical sector is expected to undergo a value reassessment, with managers identifying high-potential companies in niche areas for early investment [6] - Controllable nuclear fusion is attracting strategic bets, with funds focusing on companies within the nuclear fusion supply chain, anticipating significant revenue potential despite the technology's current stage [6] Emerging Investment Trends - The Beijing Stock Exchange has become a new hotspot for fund establishment, with new funds rapidly completing high-position layouts, indicating increased institutional participation in small and medium-sized growth enterprises [7]